Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia

Fever during a neutropenic episode in patients receiving chemotherapy or immunosuppressive therapy is a medical emergency requiring prompt administration of empirical antimicrobial therapy. Existing guidelines for the management of febrile neutropenia (FN), such as those by the Infectious Diseases Society of America (IDSA), recommend that high-risk patients are hospitalised and are treated with intravenous antibiotics. Monotherapy is now preferred over combination antimicrobial therapy [1]. Piperacillin/tazobactam (TZP), carbapenems [meropenem or imipenem/cilastatin (IPM/CS)] and antipseudomonal cephalosporins (e.g.

Source: International Journal of Antimicrobial Agents - May 9, 2018 Category: Drugs & Pharmacology Authors: Ai Leng Khoo, Ying Jiao Zhao, Monica Teng, Ding Ying, Jing Jin, Yen Lin Chee, Li Mei Poon, Siew Eng Lim, Liang Piu Koh, Wee Joo Chng, Boon Peng Lim, Li Yang Hsu, Louis Yi Ann Chai Source Type: research